'Real-life' experience in asthmatic children treated with omalizumab up to six-years follow-up.

CONCLUSIONS: Overall in 'real life' omalizumab in children reduces asthma exacerbations and hospitalizations, improves lung function, and decreases the maintenance therapy. It is shown to be safe for up to six years of treatment in children.
PMID: 30509559 [PubMed - as supplied by publisher]

Source: Allergologia et Immunopathologia - November 30, 2018 Category: Allergy & Immunology Authors: Folqué MM, Lozano J, Riggioni C, Piquer M, Álvaro M, Machinena A, Giner MT, Domínguez O, Jiménez-Feijoo RM, Dias da Costa M, Plaza AM Tags: Allergol Immunopathol (Madr) Source Type: research